Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Best of the Blog: START-UP May/June 2009

This article was originally published in Start Up

Executive Summary

Our favorite blog posts from May and June related to stories not covered elsewhere in this issue of Start-Up.

You may also be interested in...

GSK Tries to Mimic Real-World Biotech

Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.

Vitae's Debt Financing: Crucial Lifeline in a Tightening Financial Market

Roughly one week after GlaxoSmithKline gave Vitae Pharmaceuticals back rights to its renin inhibitor, the biotech signed a $13 million loan deal with Silicon Valley Bank and Oxford Finance, providing a cash runway at least into 2010. The cash lifeline was relatively small in dollar value but significant for even happening in the first place. The hard economic times have all but shut down the venture capital supply, leaving serious questions about money strategies for other biotechs.

A Place for Discovery in Biotech--in Which Discovery Knows Its Place

In a product-oriented world, most biotechs learn to de-emphasize discovery, or even abandon it, in favor of in-licensing-as Vitae appeared to do when it in-licensed a series of molecules from Allergan. But Vitae's recent discovery-stage deal with GlaxoSmithkline, and the follow-on financing that followed it, shows that high-value small-molecule discovery deals can happen and provide valuation increases. But it's the very unusual company that can afford to focus its business entirely on them.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts